Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment
NCT00134953 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2007-12-17
Summary
This study is designed to investigate the efficacy and safety of rivastigmine compared with placebo in patients with mild cognitive impairment (MCI).
Conditions
- Cognitive Symptoms
Interventions
- DRUG
-
Rivastigmine
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals Corporation · Novartis Pharmaceuticals
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 50 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-01-31
- Completion
- 2004-05-31
More Related Trials
-
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
NCT01529619 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
NCT00099216 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
NCT00104442 ·Status: COMPLETED ·Phase: PHASE4
-
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
NCT01399125 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
NCT00561392 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
NCT00948766 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease
NCT02221947 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
NCT00423085 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients
NCT01602198 ·Status: TERMINATED ·Phase: NA
-
NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.
NCT02703636 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine
NCT01380288 ·Status: COMPLETED ·Phase: NA
-
Rivastigmine in the Management of Delirium
NCT01487317 ·Status: COMPLETED ·Phase: PHASE3
-
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
NCT00731224 ·Status: COMPLETED ·Phase: PHASE4
-
Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial
NCT00835159 ·Status: COMPLETED ·Phase: PHASE4
-
Rivastigmine in Mild Alzheimer's Disease, FMRI Study
NCT00627848 ·Status: COMPLETED ·Phase: NA
-
Rivastigmine Mini-Tablet for Alzheimer's Disease
NCT06828289 ·Status: NOT_YET_RECRUITING
-
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients
NCT00202540 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease
NCT00305903 ·Status: COMPLETED ·Phase: PHASE4
-
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
NCT00622713 ·Status: COMPLETED ·Phase: PHASE4
-
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00234637 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.
NCT01117948 ·Status: TERMINATED ·Phase: PHASE2
-
Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment
NCT02573740 ·Status: TERMINATED ·Phase: PHASE1
-
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
NCT02989402 ·Status: COMPLETED ·Phase: PHASE4